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Abstract
Background: Lipodystrophy syndromes comprise a group of extremely rare and heterogeneous diseases
characterized by a selective loss of adipose tissue in the absence of nutritional deprivation or catabolic state.
Because of the rarity of each lipodystrophy subform, research in this area is difficult and international co-operation
mandatory. Therefore, in 2016, the European Consortium of Lipodystrophies (ECLip) decided to create a registry for
patients with lipodystrophy.
Results: The registry was build using the information technology Open Source Registry System for Rare Diseases in
the EU (OSSE), an open-source software and toolbox. Lipodystrophy specific data forms were developed based on
current knowledge of typical signs and symptoms of lipodystrophy. The platform complies with the new General
Data Protection Regulation (EU) 2016/679 by ensuring patient pseudonymization, informational separation of
powers, secure data storage and security of communication, user authentication, person specific access to data, and
recording of access granted to any data. Inclusion criteria are all patients with any form of lipodystrophy (with the
exception of HIV-associated lipodystrophy). So far 246 patients from nine centres (Amsterdam, Bologna, Izmir,
Leipzig, Münster, Moscow, Pisa, Santiago de Compostela, Ulm) have been recruited. With the help from the six
centres on the brink of recruitment (Cambridge, Lille, Nicosia, Paris, Porto, Rome) this number is expected to double
within the next one or 2 years.
Conclusions: A European registry for all patients with lipodystrophy will provide a platform for improved research
in the area of lipodystrophy. All physicians from Europe and neighbouring countries caring for patients with
lipodystrophy are invited to participate in the ECLip Registry.
Study registration: ClinicalTrials.gov (NCT03553420). Registered 14 March 2018, retrospectively registered.
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Introduction
Lipodystrophy syndromes form a heterogeneous group
of diseases characterized by a selective loss of adipose
tissue, sometimes associated with fat accumulation in
other regions of the body, in the absence of nutritional
deprivation or catabolic state [1]. Lipodystrophy syn-
dromes have been traditionally divided into four major
categories [2]: congenital generalized lipodystrophy
(CGL), familial partial lipodystrophy (FPLD), acquired
generalized lipodystrophy (AGL) and acquired partial
lipodystrophy (APL). Additionally, systemic forms
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: david.araujo@usc.es; martin.wabitsch@uniklinik-ulm.de
David Araújo-Vilar and Martin Wabitsch: Shared last author and
corresponding authorship.
Julia von Schnurbein, Giovanni Ceccarini, Gabriele Nagel, David B Savage,
Ekaterina Sorkina, Marie-Christine Vantyghem, Camille Vatier, David Araújo-
Vilar and Martin Wabitsch: ECLip Registry board member.
23Thyroid and Metabolic Diseases Unit, Centro de Investigación en Medicina
Molecular y Enfermedades Crónicas (CIMUS)-IDIS, School of Medicine,
Universidade de Santiago de Compostela, Avda. Barcelona 3, 15707 Santiago
de Compostela, Spain
1Division of Paediatric Endocrinology and Diabetes, Department of
Paediatrics and Adolescent Medicine, Centre for Rare Endocrine Disorders,
Ulm University Medical Centre, Eythstraße 24, 89075 Ulm, Germany
Full list of author information is available at the end of the article
Schnurbein et al. Orphanet Journal of Rare Diseases           (2020) 15:17 
https://doi.org/10.1186/s13023-020-1295-y
associated with progeroid or other syndromes and ac-
quired localized forms have been described. In total, this
currently subsumes about 50 different subtypes of lipo-
dystrophy (Table 1 [3]); a number which is growing
regularly, illustrating the fact that lipodystrophy can re-
sult from many different pathophysiological mechanisms
targeting adipose tissue, many of which are still to be
discovered.
One major cause for comorbidities in lipodystrophy
syndromes is the fat loss itself. Depending on the extent
Table 1. List of lipodystrophy subformes (adapted from [3]).
1 Congenital (Familial)
1.1 Generalized (CGL)
1.1.1 Type 1 CGL (AGPAT2, recessive, OMIM #608594)
1.1.2 Type 2 CGL (BSCL2, recessive, OMIM #269700)
1.1.3 Type 3 CGL (CAV1, recessive, OMIM #612526)
1.1.4 Type 4 CGL (PTRF, recessive, OMIM #613327)
1.1.5 PPARG -associated CGL (PPARG, recessive)
1.1.6 CGL with progressive encephalopathy (OMIM: #615924)
1.1.7 CGL undefined
1.2 Partial
1.2.1 Type 1 FPLD (Köbberling syndrome; genes unknown, OMIM
%608600)
1.2.2 Type 2 FPLD (Dunnigan disease; LMNA, (co-)dominant, OMIM
#151660)
1.2.3 Type 3 FPLD (PPARG , dominant, OMIM #604367)
1.2.4 Type 4 FPLD (PLIN1, dominant, OMIM #613877)
1.2.5 Type 5 FPLD (CIDEC, recessive, OMIM #615238)
1.2.6 Type 6 FPLD (LIPE, recessive, OMIM #615980)
1.2.7 Type 7 FPLD with congenital cataracts, and
neurodegeneration (CAV1, dominant, OMIM
1.2.8 AKT2-linked lipodystrophy (AKT2, dominant)
1.2.9 MFN2 associated FPLD (MFN2)
1.3 Systemic
1.3.1 Progeroid syndromes
1.3.1.1 Hutchinson-Gilford progeria syndrome (LMNA, dominant,
OMIM #176670)
1.3.1.2 Atypical Werner syndrome and atypical progeroid
syndrome (LMNA-associated)
1.3.1.3 SHORT syndrome (PIK3R1, dominant, OMIM #269880)
1.3.1.4 MDPL syndrome (generalized or partial; POLD1, dominant,
OMIM #615381)
1.3.1.5 Keppen-Lubinsky syndrome (KCNJ6, dominant, OMIM
#614098)
1.3.1.6 Néstor-Guillermo progeria syndrome (BANF1, recessive,
OMIM #614008)
1.3.1.7 Mandibuloacral dysplasia, type B (ZMPSTE24, recessive,
OMIM #608612)
1.3.1.8 Ruijs-Aalfs syndrome (SPRTN, recessive, OMIM #616200)
1.3.1.9 Cockayne syndrome type B (ERCC6, recessive, OMIM
#133540)
1.3.1.10 Cockayne syndrome type A (ERCC8, recessive, OMIM
#216400)
1.3.1.11 Lipodystrophy-intellectual disability-deafness syndrome
(Rajab-Spranger syndrome, OMIM %608154)
1.3.1.12 Marfan syndrome with neonatal progeroid –like
lipodystrophy (FBN1, dominant, OMIM #616914)
1.3.1.13 CAV1-associated neonatal onset lipodystrophy syndrome
(CAV1, dominant)
1.3.1.14 Werner syndrome (WRN/RECQL2, recessive, OMIM
#277700)
Table 1. List of lipodystrophy subformes (adapted from [3]).
(Continued)
1.3.1.15 Mandibuloacral dysplasia type A (LMNA, recessive, OMIM
#248370)
1.3.1.16 PCYT1A lipodystrophy (PCYT1A, recessive)
1.3.1.17 Wiedemann Rautenstrauch syndrome (POLR3A, recessive,
OMIM #264090)
1.3.1.18 Fontaine progeroid syndrome (SLC25A24, de novo,
OMIM # 612289)
1.3.2 Autoinflammatory syndromes, ALDD (generalized or partial)
1.3.2.1 PRAAS 1 (PSMB8, recessive or digenic with PSMA3 or
PSMB4, OMIM #256040)
1.3.2.2 PRAAS 2 (POMP, dominant, OMIM #618048)
1.3.2.3 PRAAS3 (PSMB4, recessive or digenic with PSMB9, OMIM
#617591)
1.3.2.4 Panniculitis-associated lipodystrophy (OTULIN, recessive,
OMIM #617099)
1.3.3 Others
1.3.3.1. Optic atrophy, cataracts, lipodystrophy/lipoatrophy,
peripheral neuropathy (OPA3, dominant, OMIM #165300)
2 Acquired
2.1 Generalized
2.1.1 Acquired generalized lipodystrophy, idiopathic
2.1.2 Acquired generalized lipodystrophy, autoimmune
2.1.3 Acquired generalized lipodystrophy, panniculitis
2.2 Partial (excluding HIV associated lipodystrophy)
2.2.1 Acquired partial lipodystrophy (Barraquer-Simons syndrome,
OMIM #608709)
2.2.2 Lipodystrophy associated with total body irradiation and
hematopoietic stem cell transplant
2.2.3 Acquired partial lipodystrophy, undefined
2.3 Localized
2.3.1 Lipodystrophy caused by drug injections
2.3.2 Lipodystrophy semicircularis
2.3.3 Centrifugal lipodystrophy
2.3.4 Progressive hemifacial atrophy (Parry Romberg syndrome,
OMIM % 141300)
2.3.5 Idiopathic localized lipodystrophy
2.3.6 Panniculitis induced localized lipodystrophy
CGL Congenital generalized lipodystrophy, FPLD Familial partial lipodystrophy,
PRAAS Proteasome-associated auto-inflammatory syndrome
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of fat loss (and also varying according to subtype, age,
gender, and some yet unidentified factors) the deficient
adipose mass results in ectopic lipid storage in various
organs including liver and muscles which can cause a se-
vere insulin resistance, hypertriglyceridemia, and non-
alcoholic fatty liver disease. This in turn may lead to se-
vere complications such as diabetes, cardiovascular dis-
ease, liver cirrhosis, ovarian dysfunction, and acute
pancreatitis. In addition, each lipodystrophy subform has
specific and greatly varying comorbidities which include
muscular and/or neurological manifestations and anom-
alies of skin, skeleton, and internal organs. The pheno-
typic expressivity of each lipodystrophy subform and the
associated co-morbidities and their prognosis is ex-
tremely variable, even within each category.
With the exception of HIV-associated lipodystrophy,
lipodystrophy syndromes are extremely infrequent [1].
The prevalence figures that are being considered vary
tremendously, largely due to the difficulty of gathering
representative series of sufficient size. Thus, the preva-
lence for infrequent lipodystrophy subforms has been es-
timated as 1 in 10 million [4]. Based on the study of a
series of databases of electronic medical records and
analysis of European literature since 2000, the global
prevalence for all lipodystrophy subforms was recently
estimated as 1.3–4.7 per million, being 0.23 per million
for generalized forms and 2.84 for partial forms [5]. For
certain subtypes, even only a handful of cases have been
reported [6, 7]. However, it is likely that lipodystrophy
syndromes are underdiagnosed, especially partial forms
of the disease [8–10].
The low prevalence of lipodystrophy syndromes com-
bined with the huge heterogeneity in phenotype and
genotype make it difficult, if not impossible, for a single
centre or research group to describe new genetic and/or
environmental determinants of specific forms and to
study the natural history of these heterogeneous condi-
tions, the associated complications and co-morbidities,
the response to different management strategies, and
prognosis including mortality rate.
Hence it is clear that an international approach is
needed, in which multiple groups experienced in diag-
nostics and management of lipodystrophy syndromes
participate.
In Bologna in 2014, a group of scientists devoted to
lipodystrophy syndromes founded the European Consor-
tium of Lipodystrophies, ECLip [11], as a tool that allows
the exchange of knowledge, skills and ideas to advance
research in the field of lipodystrophy, and that will en-
able the implementation of common research projects.
Today, more than 30 groups from 20 European coun-
tries participate in this consortium, with annual meet-
ings where advances and achievements of all facets in
the field of lipodystrophy are presented and discussed.
In 2016, the consortium decided to found a European
Registry of Lipodystrophies.
By creating one central, international registry combin-
ing data from centres all over Europe and neighbouring
countries, not only can data be collected on all clinical
and molecular aspects related to the syndromes, but also
virtual information can be included about the availability
of biological samples from the patients for basic re-
searchers to elucidate new pathogenic mechanisms.
The aim of this manuscript is to present the goals pur-
sued in the short, medium and long term by the Euro-
pean Registry of Lipodystrophies, its structure and the
basis that govern its internal functioning. It is also an in-
vitation to other groups to collaborate in this common
effort to unravel the different basic and clinical aspects
of lipodystrophy syndromes that to this day still remain
undisclosed.
Methods
Aim of the registry
The aim of this registry is to enable physicians within
but also outside of Europe to work together in the field
of lipodystrophy and to accumulate sufficient data for
sound research in this area.
This aim can be achieved by three different ap-
proaches within the registry:
First, by striving to engage all active centres caring for
patients with lipodystrophy in Europe, the registry aims to
provide the basis for an improved estimate of the
prevalence of lipodystrophy in Europe.
Second, the registry offers a firm basis for patient-
centred clinical lipodystrophy research, for instance on
the natural course of various lipodystrophy syndromes,
comorbidities, family history, and management strat-
egies and outcomes. Thus, the registry will contribute
to research areas currently not well examined due to
the extreme rarity of some lipodystrophy subforms.
Third, the registry provides a platform for nested
investigations on specific clinical, molecular and
functional topics. Patients with a particular lipodystrophy
subform can be identified via the registry and invited for
specific research projects through the physician who
enrolled her or him in the registry. Due to the flexibility
of the employed IT structure (see below), the results of
such research projects can also be documented in the
registry. This not only enables researchers of this specific
project to use all previously documented information of
the patients but also makes the raw data of this project
available to future projects and researchers.
Quality aspects of the registry
We attempt to reach a high level of compliance to inter-
national quality standards for rare disease registries. We
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adhere as closely as possible to the standard described
for the two domains research quality and evidence qual-
ity as published earlier [12]. The operational aspects of
the registry are based on the standards defined by the
European Platform for Rare Disease Registries 2011–
2014 (EPIRARE) survey [13]. In addition, the registry fol-
lows the FAIR principles [14] ensuring that (meta) data
are findable, accessible, interoperable and reusable for
example by using international accepted coding for diag-
nosis (ICD 10, OrphanCode and OMIM code) and treat-
ment (Anatomical Therapeutic Chemical (ATC)
Classification System).
To avoid duplicate entries of a patient, the data set en-
tered for each new patient is checked automatically by
the pseudonymization tool for correspondence with
existing data sets (record linkage). Depending on the de-
gree of IDAT correspondence, a new data set is created
or an existing one re-turned. In addition, the Institute of
Epidemiology and Medical Biometry of the Ulm Univer-
sity will biannually perform data plausibility checks.
Retrospective data (for example from deceased patients)
will be marked as such to differentiate from prospect-
ively collected data.
Government of the ECLip registry
The European Registry of Lipodystrophies [15] has been
developed and is supported by public institutions (uni-
versities and research centres), independent of private
companies. The head of the registry are the ECLip
Registry members. Any physician or scientist seeing pa-
tients with lipodystrophy who wants to participate can
apply at the registry board (see below) to become a
member of the registry. Apart from a positive vote by
the board, the centre also has to obtain approval by their
local ethics committee to participate in the registry. All
registry members can attend the registry members meet-
ing, which is being hold annually as part of the ECLip
meetings. There is one vote for every institution with
one (or more) registry member.
All ECLip members are entitled to decide over re-
search projects from third parties and major changes to
the registry. They also elect 7–10 (currently 9) ECLip
members to form the registry board for a period of 3
years.
The registry board is the governing body of the regis-
try and responsible for managing the registry. It controls
the data storage and the Local Operating Group (see
below), votes on research proposals from ECLip mem-
bers, improves the registry, decides who can become
registry member, and processes requests to inform indi-
vidual physicians about specific research results import-
ant for their patients. In addition, for each research
project a contact person from the registry board will be
selected who will support this specific project and will
be part of the research team of this project. Further-
more, in order to guarantee the quality of the data, on a
6 months rotating basis a member of the registry board
acts as curator. The curator ensures that all the data en-
tered in the registry are correct, and that there are no
crude inconsistencies between the proposed diagnosis
and the phenotype described.
The registry board is being supported by a Local Oper-
ating Group consisting of a member of the Open Source
Registry System for Rare Diseases in the EU (OSSE)
team (see below) and the people from the Institute of
Epidemiology and Medical Biometry of the Ulm Univer-
sity working in the project including the IT administra-
tor. Duties of the Local Operating Group are
implementation of improvements in the registry, mer-
ging and deletion of patients if necessary, creation of
new users, maintenance of the data set, and support and
provision of data for research projects.
As the servers for the registry are based at the Univer-
sity of Ulm, the stewardship of the registry data falls to
the University of Ulm.
Set-up of the ECLip registry
Open source registry system for rare diseases in the EU
The ECLip Registry has been set up using OSSE [16], an
open source software and toolbox. The Open Source
Software OSSE has been specifically designed as a frame-
work and an organizational process to set up a rare dis-
ease specific registry [14]. The fundamental goal of
OSSE is to provide patient associations, physicians and
other stakeholders the opportunity to create and estab-
lish a patient registry without extensive IT knowledge.
Data processing components
The OSSE registry software for the ECLip Registry pro-
vides the recording and storage of basic and longitudinal
medical data of patients affected by lipodystrophy (Fig.
1). Data fields and forms are specifically designed to fit
the description of lipodystrophy syndromes (Table 2).
These forms and fields can be modified and supple-
mented throughout the running registry. Data fields
used in the registry are created via the Meta Data Re-
pository (MDR) as data elements (Fig. 1). The MDR of-
fers a controlled vocabulary and can provide machine-
readable, structured information on data elements, e.g.
conceptual domains or value ranges. Data elements are
used in forms that are used to enter patient data in the
registry.
Data protection
The platform is designed to comply with all current data
protection requirements specifically the General Data
Protection Regulation (EU) 2016/679 by the following
procedures:
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Pseudonymization
The most important procedure for data protection is pa-
tient pseudonymization. The personal identification data
of the patients (IDAT) are assigned a random code
(pseudonym) by using a pseudonymization tool called
Mainzelliste. Mainzelliste is an open-source software to
create and manage patient-pseudonyms in research pro-
jects [17]. It creates a unique identifier (PID) and a
second-level pseudonym (PSNOSSE) for each patient.
When a pseudonym is requested by the OSSE registry,
Mainzelliste checks the data set for correspondence with
existing data sets (record linkage). Depending on the de-
gree of IDAT correspondence, a new data set is created
or an existing one returned (Fig. 1).
Communication between the identity management
and the OSSE registry happens via a web browser. A
temporary identifier ensures that the treating physician
can see the identity (ID) management’s entry mask (the
patient’s name) integrated into the user interface to-
gether with the corresponding medical data (MDAT) of
his or her patient. However, the returned pseudonym of
the patient, “PSNOSSE”, is not shown to the physician
though it is stored together with the MDAT. Thereby it
becomes impossible to correlate IDAT and PSNOSSE out-
side the ID management system even manually (Fig. 1).
Informational separation of powers
IDAT and the clinical information of the patients are
housed on separate (and adequately protected) servers
(Fig. 1). These servers are logically, physically and
organizationally independent.
The institution in charge of ID management (the Insti-
tute of Epidemiology and Medical Biometry of the Ulm
University) operates its own legal responsibility and is
not subject to the directives of the registry management.
This ensures that individuals with access to clinical or
Fig. 1 Data transfer within the ECLip Registry. Figure 1 shows data transfer within the ECLip Registry from the patient to two separate servers
localized at Ulm University. The online tool Mainzelliste provides patients pseudonyms whereas the metadata repository is stored at the provider
of the IT structure, OSSE. OSSE: Open Source Registry System for Rare Diseases in the EU, PID: unique patient identifier, PNSOSSE:
second-level pseudonym
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biomaterial data in the ECLip Registry outside the treat-
ment context are not able to correlate the data to a
patient.
Access to data
Each participating physician can only access data of the
patients in his or her centre, but not those of others. Ac-
cess to data is also provided to each patient interested in
his or her own data. For data evaluation purposes, access
to pseudonymised data of a patient cohort is granted
only after approval of a data evaluation concept (see
below). For this purpose, the patient data are exported
with a new pseudonym ensuring that the data recipient
can’t see the pseudonym of the data owner. Further
methods to ensure data protection included secure data
storage on encrypted hard drive partitions, security of
communication via encrypted connections and firewall
protection, user authentication via a username and pass-
word, and recording of access granted to any data.
Patient recruitment; inclusion and exclusion criteria
All patients of all ages with any form of lipodystrophy
presenting at a participating centre are asked to partici-
pate in the ECLip Registry. The only exclusion criterion
is HIV-associated lipodystrophy. After written informed
consent is reached, pseudonymised patient data can be
entered into the registry. In most centres, ethical ap-
proval also covers inclusion of data of patients deceased
or lost to follow-up in an anonymous way, because lipo-
dystrophy syndromes are so rare that any information
that can be gathered can be of vital importance for fu-
ture patients.
Data collection, documentation and evaluation and
statistical considerations
Data collection and documentation Data entry is done
at the individual locations via the web-based user inter-
face; additionally, data can also be collected via data im-
port interfaces. Also in this case, data pseudonymization
takes place at the time-point of data entry. Based on the
current knowledge about lipodystrophy syndromes in-
cluding the recently published consensus paper [1], lipo-
dystrophy specific data forms have been developed to
cover all medical information relevant to patients with
lipodystrophy (Table 2 and Additional file 1).
These data collection forms exist also in paper form
(see Additional file 1) and can be used directly in the
physician’s office at the time of presentation of the pa-
tient. They provide a valuable tool to ensure in-depth
analysis of the patient’s signs and symptoms. The data
can then be transferred into the electronic systems
which reflect the same data forms and structure.
The information gathered within the ECLip Registry is
structured into three different blocks (Fig. 1):
A first block collects the personal data of the patients
(IDAT; stored separately, see above). A second block
collects basic information on informed consent and per-
manent medical data of the patient including demo-
graphic data, diagnosis, genetic information if available,
death (if applicable), family history, and local availability
of biological samples (see below).
The third block collects information of each episode.
An episode is defined as each clinical evaluation made of
Table 2 Overview of assessments in the ECLip Registry
Identifying data
name
date of birth
Basic medical data
gender
demographic data
diagnosis
genetic information if available
death (if applicable)
informed consent
family history
local availability of biological samples
hypothesis related questions
Data for each episode
anthropometric data and vital signs
adipose tissue
skinfold values
anatomical distribution of the lipoatrophic and lipohypertrophic regions
analysis of body composition by dual-energy X-ray absorptiometry
signs and symptoms in the following organ systems
skin & appendages
skull & face
thyroid
eyes & vision
nose
ears &hearing
mouth
heart & vascular system
abdomen & gastrointestinal organs
kidney & renal function
neuromuscular functions
bones & joints
reproductive health & pregnancy
haematology & immune system
psychosocial health
metabolic system and complications of diabetes
most recent clinical laboratory values
medication
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the patient over time; the numbers of episodes which
can be entered for each patient are not limited. In each
episode, the clinical information gathered of the patient
is sorted into anthropometric data, signs and symptoms
organized according to organ-systems, information on
psychosocial health, most recent clinical laboratory
values, and medication (Table 2 and Additional file 1).
Virtual biobank
The ECLip Registry does not set up a biobank database.
Existing samples are stored and managed locally and
organizational data attached to this will be entered
manually into the registry. For specific research pur-
poses, a temporary sample collection point can be set
up. A specific additional patient approval for this pur-
pose might be applicable according to the regulations of
each local ethics committee.
Data evaluation
If an ECLip Registry member or a third party wants to
use data of a cohort of patients in the registry for scien-
tific purposes, a formal request has to be submitted to
the registry board (or to the ECLip Registry members in
case of a third party). The request is analysed for scien-
tific soundness, feasibility, ethical considerations, and ad-
herence to the aims of the registry. If the request is
granted, a data usage contract is drawn up between all
researchers, the ECLip Registry board and all physicians
providing patient information.
Data and samples are available free of charge but a fee
to refund the costs of sample handling.
(including laboratory preperation of the sample, ad-
ministration, and shipment) and in case of a third party
organizational support (storage, maintenance) might
apply. The cost of handling samples will depend to the
characteristics of the project and the type of samples.
Statistical considerations and sample size
The ECLip Registry is conducted as a multicentre clin-
ical registry and functions as observational study con-
ducted as a cohort study.
One important aim is to provide a more accurate esti-
mation of the prevalence of lipodystrophy syndromes in
Europe. Here, countries like Spain where nearly all pa-
tients are being seen at least once in the reference centre
in Santiago de Compostella (currently following around
200 patients) can serve as basis, even though, by the dis-
tribution of diagnosed cases within Spain, it is obvious,
that in some areas lipodystrophy still is underdiagnosed
also in Spain.
Another important aim of the ECLip Registry is to
characterize the phenotype and genotype of the study
sample by sex, age groups and region and to describe
treatment patterns. Through a follow-up of the cohort it
will be possible to describe the natural course of disease
and to identify prognostic factors. Comparison and pool-
ing with other data resources will be possible. These
analyses will be mostly descriptive, but for specific re-
search questions, as for example prognostic factors, sam-
ple size calculations will be performed.
With an estimate of above 500 million inhabitants in
the EU (over 700 million in the geographical Europe)
and an estimated prevalence rate for lipodystrophy of
1.3–4.7 per million, roughly 650 to 2350 patients with
lipodystrophy are expected to live within the EU (and
910 to 3290 patients in the geographic Europe). Cur-
rently, 17 of 28 EU countries are participating in the
European Consortium of Lipodystrophies itself, and 20
of 44 European countries. We therefore aim to recruit at
least 50% of the lowest number estimated for all patients
within the EU (> 325 patients), preferably of all of Eur-
ope (> 450). So far 246 patients from nine centres
(Amsterdam, Bologna, Izmir, Leipzig, Münster, Moscow,
Pisa, Santiago de Compostela, Ulm) have been recruited.
With the help from the six centres on the brink of re-
cruitment (Cambridge, Lille, Nicosia, Paris, Porto, Rome)
this number is expected to double within the next 1 or 2
years.
Ethical considerations
The ECLip Registry tries to take into account all import-
ant ethical considerations. Each registry site has to ob-
tain approval from their local ethics committee before
participation in the registry. Participation is entirely vol-
untary for the patients and written informed consent has
to be obtained from every participating patient (with the
exception to anonymous data collection from patients
deceased or lost to follow-up as described above). Pa-
tients can withdraw their consent at any time and ac-
cording to their wishes, all their data will be either
anonymised or deleted (except for data already used in a
published study or in a study in progress).
As shown above, data protection is a fundamental as-
pect of the ECLip Registry. In addition, a further import-
ant aim is long-time preservation of the data to make it
available not only for current but also future researchers.
Future plans
The ECLip Registry is designed for a horizon of 50 years.
Periodically, every 5 years, a descriptive analysis and
publication of the data incorporated into the registry is
planned, once agreements have been reached between
the corresponding parties involved. In addition, the
registry is open to specific studies and collaborations
with third parties, both from the pharmaceutical indus-
try, and from basic research groups to launch research
projects that advance the knowledge of the molecular
basis of lipodystrophy syndromes, response to different
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management strategies or start-up of clinical trials with
new drugs.
Many of the main expert centres in the field of lipody-
strophy care and research in Europe are already involved
in the ECLip Registry. Through personal contacts and by
rising public awareness of this registry we aim to expand
the registry further to include as many centres in Europe
and neighbouring countries as possible. The registry is
already registered at Clinical Trials. In the future, regis-
tering at further data banks such as RD-Connect and
Orphanet are planned to further increase awareness of
the registry.
The ECLip registry is also involved in the European
Registries for Rare Endocrine Conditions (EuRRECa), a
new project that aims to develop a core registry and an
e-reporting programme for patients with rare endocrine
conditions in Europe [18]. One of the ECLip Registry
board members is member of a EuRRECa Expert Work-
ing Group [19] and in the future we plan to establish a
functional connection between the EuRRECa eREC sys-
tem and the ECLip OSSE Registry in order to systemat-
ically update the EuRRECa disease records on European
patients affected by lipodystrophy using an agreed core
of minimum data set.
Setting-up of the registry was encouraged by lipody-
strophy patient associations such as the “Association of
Families and People Affected by Lipodystrophy” (AELip).
Many more national lipodystrophy patient advocacy
groups are in the process of formation and they have
been invited to name one common representative as a
future ECLip Registry board member.
Discussion
The creation of registries for rare diseases is a recom-
mendation of the European Commission, and results
from the objective need to have improved information
about the prevalence of each of these diseases and also
of their natural history, associated complications, health
burden for affected individuals, response to different
management strategies, and deeper knowledge of the
aetiology and pathogenesis. A registry as an organized
system that collects clinical and other data to a given
purpose with methods of observational studies in a stan-
dardized manner is a suitable methodological approach
to address the challenges of studying rare diseases [12].
Registries for rare diseases can also be an instrument
for communication between professionals and affected
individuals (European Union Committee of Experts on
Rare Diseases (EUCERD) core recommendations on rare
disease patient registration and data collection, [20]).
They can serve as a tool for clinical benchmarks with
the aim of improving patient care. Registries are also a
Fig. 2 Map of all currently participating ECLip Registry centres (created from: www.freeworldmaps.net)
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useful tool to facilitate the implementation of clinical tri-
als and through the participation of patient associations
and experts, the identification of unmet needs of affected
individuals and their families. By increasing awareness of
a rare disease in the population and the medical com-
munity they may also help to reduce under-diagnosis
and under-treatment in the future.
As concluded recently on the basis of a survey per-
formed by a research group of the European Reference
Network on Rare Endocrine Conditions (Endo-ERN)
there is a need to improve the awareness and participa-
tion in existing registries [21]. Our paper therefore fol-
lows this recommendation and informs about the
recently developed European Registry of
Lipodystrophies.
Conclusion
The ECLip Registry is today a fully operational reality
[21] in which many expert centres in the field of lipody-
strophy syndromes from Europe and its neighbouring
countries are involved. Recruitment started on Decem-
ber 16th 2017; currently, 15 centres are so far participat-
ing all over Europe and neighbouring countries, with 9
centres already actively recruiting patients (Fig. 2). Six
further centres are also dedicated to participate. The
registry has been registered at ClinicalTrials.gov (Clini-
calTrials.gov ID: NCT03553420) and is also part of EuR-
RECa [18].
We hope that the EClip Registry will allow in the near
future to have a detailed portrait of lipodystrophy syn-
dromes in Europe and beyond, which will result in an
improvement in the welfare for and prognosis of patients
affected with lipodystrophy.
To achieve this goal, we invite all physicians and re-
searchers involved in the field of lipodystrophy to par-
ticipate in this registry.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-020-1295-y.
Additional file 1. ECLip Patient Data Sheet.
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